<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03307707</url>
  </required_header>
  <id_info>
    <org_study_id>CKD-MBD-HF</org_study_id>
    <nct_id>NCT03307707</nct_id>
  </id_info>
  <brief_title>New Heart Failure Biomarkers in Early Stage Chronic Kidney Disease-Mineral and Bone Disorder</brief_title>
  <acronym>CKD-MBD-HF</acronym>
  <official_title>Heart Failure and Early Stage Chronic Kidney Disease -Mineral Bone Disorder : the Importance of the New Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pr. Semir Nouira</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Monastir</source>
  <brief_summary>
    <textblock>
      the objective of this study is to :&#xD;
&#xD;
      -Determinate wether the circulating levels of iFGF23 and klotho can be a predictor biomarker&#xD;
      of HF in patients with CKD-MBD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The disorders of mineral metabolism and bone disease are common complications in CKD patients&#xD;
      and they are associated with increased morbidity and mortality.&#xD;
&#xD;
      Abnormalities of the vasculature are seen in early CKD, producing vascular stiffness&#xD;
      contributing to left ventricular hypertrophy and its pathophysiology involves newly&#xD;
      discovered hormones, such as the fibroblast Growth factor 23 (FGF23) and α- klotho.&#xD;
&#xD;
      The FGF receptor and its co-receptor klotho moderate these effects. FGF23 levels inflate&#xD;
      early in in the advancement of CKD stage to attain levels in CKD stage 5D.&#xD;
&#xD;
      But we still have few knoweledges if these markers can have some drawbacks for predicting CVD&#xD;
      in early stage CKD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2015</start_date>
  <completion_date type="Actual">December 30, 2015</completion_date>
  <primary_completion_date type="Actual">September 30, 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fibroblast Growth Factor 23 (FGF23)</measure>
    <time_frame>completed data base (after 4 months)</time_frame>
    <description>compare the circulating levels of FGF23 (pg/ml) in the two groups .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alpha Klotho</measure>
    <time_frame>completed data base (after 4 months)</time_frame>
    <description>compare the circulating levels of klotho (ng/ml) in the two groups .</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">111</enrollment>
  <condition>Kidney Disease, Chronic</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Heart Failure (HF)</arm_group_label>
    <description>subjects with a Left Ventricular Ejection Fraction (LVEF) &lt;50% or LVEF &gt;50% and E/e'&gt;10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Heart Failure (NHF)</arm_group_label>
    <description>subjects with LVEF&gt;50%</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples were centrifuged, the plasma were collected and stored at -80°C until&#xD;
      utilization.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        subjects who visited the emmergency departement or the nephrology departement , meeting the&#xD;
        criteria inclusion and have given a written consent .&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Early CKD stage&#xD;
&#xD;
          -  Heart failure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infections&#xD;
&#xD;
          -  cancer&#xD;
&#xD;
          -  corticoid therapy&#xD;
&#xD;
          -  renal replacement therapy&#xD;
&#xD;
          -  Advanced CKD stage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lamti Feten, PhD student</last_name>
    <role>Study Chair</role>
    <affiliation>Research Laboratory (LR12SP18) University of Monastir Tunisia, Tunisia and Research Unit (UR17ES29) Faculty of Pharmacy , Monastir</affiliation>
  </overall_official>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>October 4, 2017</study_first_submitted>
  <study_first_submitted_qc>October 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2017</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Monastir</investigator_affiliation>
    <investigator_full_name>Pr. Semir Nouira</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>FGF23</keyword>
  <keyword>klotho</keyword>
  <keyword>Mineral Bone Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

